ProShare Investment Clubs

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

6 Month Chart

More AstraZeneca charts

AstraZeneca Fundamentals

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-08	31,601.00	8,681.00	510.00¢	8.6	0.5	+16%	205.00¢	4.7%
31-Dec-09	32,804.00	10,807.00	632.00¢	7.2	0.3	+24%	230.00¢	5.1%
31-Dec-10	33,269.00	10,977.00	671.00¢	6.8	1.1	+6%	255.00¢	5.6%
31-Dec-11	33,591.00	12,367.00	728.00¢	6.4	0.8	+8%	280.00¢	6.0%
31-Dec-12	27,973.00	7,718.00	641.00¢	7.1	n/a	-12%	280.00¢	6.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-13	16,915.26	4,470.92	334.37p	9.7	n/a	-18%	179.58p	5.5%
31-Dec-14	16,374.11	4,497.39	319.07p	10.2	n/a	-5%	181.57p	5.6%

AstraZeneca forecasts

AstraZeneca Company Announcements

Director/PDMR Shareholding	12-Jun-2013	15:00	RNS
Director/PDMR Shareholding	12-Jun-2013	15:00	RNS
Director/PDMR Shareholding	12-Jun-2013	15:00	RNS

More astrazeneca company announcements

AstraZeneca ShareCast News

AstraZeneca sets up new headquarters in Cambridge	18-Jun-2013	ShareCast
Tuesday tips round-up: Xaar, AstraZeneca, Gemfie...	11-Jun-2013	ShareCast
Broker tips: Lloyds, AstraZeneca, Betfair	10-Jun-2013	ShareCast

More AstraZeneca ShareCast news

AstraZeneca Top Newspaper Links

New partnership to fight diabetes	18-Jun-2013	Express & Star
AstraZeneca seals deal for lung drug firm	11-Jun-2013	Express & Star
AstraZeneca to buy US respiratory drug specialis...	11-Jun-2013	Guardian

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Price Data

Currency	UK Pounds
Share Price	3,250.50p
Change Today	4.00p
% Change	0.12 %
Volume	1,587,217
18-Jun-13 Close	3,250.50p
Shares Issued	1,252.09m
Market Cap	£40,699m
Year End	31-Dec-12

What The Brokers Say

Strong Buy	3
Buy	0
Neutral	22
Sell	4
Strong Sell	7
Total	36

Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Latest recommendations

Broker consensus analysis

AstraZeneca Dividends

	Latest	Previous
	2nd Interim	1st Interim
Ex-Div	13-Feb-13	08-Aug-12
Paid	18-Mar-13	10-Sep-12
Amount	190.00¢	90.00¢

Trades for 18-Jun-2013

Time	Volume / Share Price
16:58	5,698 @ 3,249.57p
16:44	13,283 @ 3,248.63p
16:44	5,970 @ 3,254.52p
16:35	93 @ 3,250.50p
16:35	326,677 @ 3,250.50p

More AstraZeneca trades data

AstraZeneca Key Personnel

CEO	Pascal Soriot

More AstraZeneca corporate information